Dianthus Therapeutics, Inc. /DE/ (DNTH): Nasdaq/NYSE listing notice — Magenta Therapeutics halts all programs, explores strategic alternatives

Dianthus Therapeutics, Inc. /DE/

Halts all development programs; will explore strategic alternatives including acquisition, merger, or business combination.
Received Nasdaq deficiency notice for common stock bid price below $1.00 for 30 consecutive trading days.
Has 180 days (until July 31, 2023) to regain compliance with minimum bid price requirement.
No timetable set for strategic review; no assurance a transaction will be completed.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Dianthus Therapeutics, Inc. /DE/ received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5810(c)(3)(A)

Exact text from the filing

January 31, 2023, Magenta Therapeutics, Inc. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that, for the 30 consecutive business day period between December 15, 2022 through January 30, 2023, the Company’s common stock, $0.001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-23-022825

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.